Revolution Medicines, Inc. (RVMD)Healthcare | Biotechnology | Redwood City, United States | NasdaqGS
207.88 USD
-13.27
(-6.000%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 208.55 +0.67 (0.322%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:59 a.m. EDT
Revolution Medicines presents a classic biotech dilemma: a fortress balance sheet with $3.9 billion in cash against a burning cash rate and negative earnings. The short-term outlook is driven by aggressive momentum; the stock is trading near its 52-week high, well above its 200-day average, and recent price action shows a strong upward trend. This technical strength justifies a high short-term rating, as speculators are actively buying calls and positioning for volatility. However, the long-term picture is clouded by the lack of profitability. Despite the strong cash position, the company generates negative operating cash flow and has negative return on equity, meaning it is not yet a cash-flow-positive machine. The five-year price trajectory is positive, but the fundamentals do not yet support a 'buy-and-hold' conviction. Investors are betting on a potential blockbuster drug, but until revenue and earnings turn positive, this remains a high-risk speculation rather than a solid investment. The options market agrees with this tension, pricing in high volatility with a slight bullish skew. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044852 |
| AutoARIMA | 0.140055 |
| AutoETS | 0.140057 |
| MSTL | 0.144470 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.29 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.745 |
| Excess Kurtosis | -0.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 45.678 |
| Market Cap | 44,556,255,232 |
| Forward P/E | -33.55 |
| Beta | 1.40 |
| Website | https://www.revmed.com |
As of Aug. 22, 2026, 4:59 a.m. EDT: Implied volatility remains elevated across all expirations, ranging from 50% to 60%, indicating heightened uncertainty. Call open interest is concentrated near the current price ($180-$210) with significant volume spikes at $230-$280 strikes, suggesting speculative bullish positioning. Put open interest is heavy at lower strikes ($90-$180), reflecting hedging activity and downside protection. The call-to-put ratio favors a bullish bias in the near term, though the high IV suggests traders expect significant price swings rather than a steady directional move.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.824335 |
| Address1 | 700 Saginaw Drive |
| All Time High | 224.31 |
| All Time Low | 14.08 |
| Ask | 207.63 |
| Ask Size | 1 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,973,020 |
| Average Daily Volume3 Month | 2,538,660 |
| Average Volume | 2,538,660 |
| Average Volume10Days | 1,973,020 |
| Beta | 1.403 |
| Bid | 207.94 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 7.493 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 207.88 |
| Current Ratio | 11.378 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 220.81 |
| Day Low | 205.82 |
| Debt To Equity | 45.678 |
| Display Name | Revolution Medicines |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -1,618,188,032 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -25.837 |
| Enterprise Value | 41,808,756,736 |
| Eps Current Year | -9.76434 |
| Eps Forward | -6.19664 |
| Eps Trailing Twelve Months | -8.87 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 191.7997 |
| Fifty Day Average Change | 16.080307 |
| Fifty Day Average Change Percent | 0.08383907 |
| Fifty Two Week Change Percent | 482.4335 |
| Fifty Two Week High | 224.31 |
| Fifty Two Week High Change | -16.429993 |
| Fifty Two Week High Change Percent | -0.073246814 |
| Fifty Two Week Low | 37.56 |
| Fifty Two Week Low Change | 170.32 |
| Fifty Two Week Low Change Percent | 4.534611 |
| Fifty Two Week Range | 37.56 - 224.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,581,604,200,000 |
| Float Shares | 184,460,065 |
| Forward Eps | -6.19664 |
| Forward P E | -33.547215 |
| Free Cashflow | -711,607,360 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 883 |
| Fullday Change | -13.27 |
| Fullday Change Percent | -6.00045 |
| Fullday Price | 208.55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Gross Profits | -1,296,338,048 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01874 |
| Held Percent Institutions | 1.01042 |
| Implied Shares Outstanding | 214,336,418 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. |
| Long Name | Revolution Medicines, Inc. |
| Market | us_market |
| Market Cap | 44,556,255,232 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_283775412 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -1,768,285,056 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 47,413,359,025 |
| Number Of Analyst Opinions | 21 |
| Open | 220.72 |
| Operating Cashflow | -1,223,032,960 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 481 6801 |
| Post Market Change | 0.66999817 |
| Post Market Change Percent | 0.32230043 |
| Post Market Price | 208.55 |
| Post Market Time | 1,787,961,575 |
| Previous Close | 221.15 |
| Price Eps Current Year | -21.289713 |
| Price Hint | 2 |
| Price To Book | 27.743227 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.122 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.27273 |
| Region | US |
| Regular Market Change | -13.27 |
| Regular Market Change Percent | -6.00045 |
| Regular Market Day High | 220.81 |
| Regular Market Day Low | 205.82 |
| Regular Market Day Range | 205.82 - 220.81 |
| Regular Market Open | 220.72 |
| Regular Market Previous Close | 221.15 |
| Regular Market Price | 207.88 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 2,004,020 |
| Return On Assets | -0.30122 |
| Return On Equity | -0.79089 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 214,336,418 |
| Shares Percent Shares Out | 0.045300003 |
| Shares Short | 9,716,949 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 14,002,778 |
| Short Name | Revolution Medicines, Inc. |
| Short Percent Of Float | 0.0479 |
| Short Ratio | 5.49 |
| Source Interval | 15 |
| State | CA |
| Symbol | RVMD |
| Target High Price | 320.0 |
| Target Low Price | 179.0 |
| Target Mean Price | 235.82143 |
| Target Median Price | 239.0 |
| Total Cash | 3,937,968,896 |
| Total Cash Per Share | 18.373 |
| Total Debt | 1,190,470,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -8.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 129.75818 |
| Two Hundred Day Average Change | 78.121826 |
| Two Hundred Day Average Change Percent | 0.60205704 |
| Type Disp | Equity |
| Volume | 2,004,020 |
| Website | https://www.revmed.com |
| Zip | 94,063 |